Coya reports Q3 net loss $3.4M, cash $10.9M; Phase 2 AD topline due summer 2024

Coya Therapeutics, Inc.

2023-Q3 EPS reported -$0.94

Net loss $3.4M ($0.34/share) vs $4.0M ($1.55/share) in Q3 2022; cash $10.9M up from $5.9M at Dec 2022.
R&D expenses $1.6M, G&A $2.0M; net loss per share improved due to increase in shares outstanding to 9.95M.
Completed enrollment (38 patients) in Phase 2 double-blind placebo-controlled trial of LD IL-2 in Alzheimer's; topline data expected summer 2024.
Plan to submit IND for Phase 2 trial of COYA 302 in ALS in 1H 2024; also licensed exosome engineering technology from Carnegie Mellon.
Appointed Dieter Weinand to board, Dr. Fred Grossman as President & CMO, and Dr. Merit Cudkowicz as clinical advisor in recent months.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Coya Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 8, 2023, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal quarter ended September 30, 2023.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060716

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.